Abstract
Over the last quarter century investigators have demonstrated that allogeneic hematopoietic cell transplantation (HCT) can cure chronic myelogenous leukemia (CML). Early reports suggested the efficacy of related donor transplant after a myeloablative preparative regimen containing total body irradiation (TBI) [1 /3]. Subsequent studies have identified variables which improve outcome such as transplant in early chronic phase, younger recipient age, donor/ recipient compatibility at the major HLA loci and male donor gender [4,5]. Myeloablative regimens which do not contain TBI have also proven effective in transplant for CML [6]. The use of peripheral blood progenitor cells as a source of stem cells for transplant mobilized with G-CSF is comparable in most respects to non-mobilized related donor marrow, although long-term studies may uncover differences in the incidence of chronic GVHD and in the risk of relapse [7].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
